UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000051336
Receipt number R000058565
Scientific Title Immune-related pancreatitis in patients with advanced cancer treated with immune-checkpoint inhibitors.
Date of disclosure of the study information 2023/06/13
Last modified on 2023/12/13 16:12:49

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Immune-related pancreatitis in patients with advanced cancer treated with immune-checkpoint inhibitors.

Acronym

Immune-related pancreatitis

Scientific Title

Immune-related pancreatitis in patients with advanced cancer treated with immune-checkpoint inhibitors.

Scientific Title:Acronym

Immune-related pancreatitis

Region

Japan


Condition

Condition

Immune-related pancreatitis

Classification by specialty

Hepato-biliary-pancreatic medicine

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To clarify the current status of immune-related pancreatitis

Basic objectives2

Others

Basic objectives -Others

Reveal the features of image findings of immune-related pancreatitis.

Trial characteristics_1

Exploratory

Trial characteristics_2

Explanatory

Developmental phase

Not applicable


Assessment

Primary outcomes

To clarify the current status of immune-related pancreatitis

Key secondary outcomes

Reveal the features of image findings of immune-related pancreatitis.


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patiens who treated by immune checkpoint inhibitors.

Key exclusion criteria

Patients who have no clinical data

Target sample size

843


Research contact person

Name of lead principal investigator

1st name Yasuki
Middle name
Last name Hori

Organization

Nagoya City University Graduate School of Medical Sciences

Division name

Gastroenterology and Metabolism

Zip code

467-8601

Address

1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Japan

TEL

+81528538211

Email

yhori@med.nagoya-cu.ac.jp


Public contact

Name of contact person

1st name Yasuki
Middle name
Last name Hori

Organization

Nagoya City University Graduate School of Medical Sciences

Division name

Gastroenterology and Metabolism

Zip code

467-8601

Address

1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Japan

TEL

+81528538211

Homepage URL


Email

yhori@med.nagoya-cu.ac.jp


Sponsor or person

Institute

Nagoya City University Graduate School of Medical Sciences

Institute

Department

Personal name



Funding Source

Organization

N/A

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Nagoya City University Graduate School of Medical Sciences

Address

1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Japan

Tel

+81528538211

Email

yhori@med.nagoya-cu.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2023 Year 06 Month 13 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2015 Year 07 Month 31 Day

Date of IRB

2022 Year 12 Month 26 Day

Anticipated trial start date

2015 Year 08 Month 01 Day

Last follow-up date

2023 Year 06 Month 01 Day

Date of closure to data entry

2023 Year 12 Month 31 Day

Date trial data considered complete


Date analysis concluded



Other

Other related information

Reveal the current status of immune-related pancreatitis.


Management information

Registered date

2023 Year 06 Month 13 Day

Last modified on

2023 Year 12 Month 13 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000058565


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name